ICG, the global alternative asset manager, today announced the appointment of Dr Samantha Budd Haeberlein as Senior Advisor to the ICG Life Sciences team. Samantha will work closely with the Life Sciences team to support and develop life science companies addressing commercially attractive markets in diseases of high unmet medical needs.
ICG’s Life Sciences team is based in London and comprises seven investment professionals bringing deep operational experience in drug discovery and development to the market. The team, led by Dr Allan Marchington, is focused on building a portfolio of 15-18 preclinical and clinical stage growth opportunities with equity investments of $25-100m per company.
Samantha is a renowned world leader in international drug development for patients with an array of neurological diseases, including a substantial background in Alzheimer’s disease, and she brings extensive experience in clinical development, translational medicine, and global regulatory experience. Samantha currently serves as the Group Chief Medical Officer of Enigma Biomedical Group where she oversees the development of therapeutic solutions to combat neurodegenerative diseases. Samantha recently held the position of Senior Vice President and Head of Neurodegeneration at Biogen, where she led and co-led the development of two revolutionary drugs, ADUHELM and LEQEMBI, both of which were approved by the FDA for the treatment of Alzheimer’s disease.
Prior to this, Samantha worked at AstraZeneca and held senior roles across research and development in the US, Canada, and Sweden. Samantha currently sits on the board of The Boston Home, a not-for-profit nursing care facility for adults with progressive neurological diseases and Vigil Neuroscience (NASDQ: VIGL) a clinical-stage biotechnology company focussed on neurodegenerative diseases.
Simon Tate, Managing Director ICG Life Sciences, said:
We are delighted to welcome Samantha to the team – her unrivalled experience in the pharmaceutical industry and the development of new drugs will prove invaluable as we evaluate exciting market opportunities and build, support and grow our portfolio.
Dr Samantha Budd Haeberlein, Senior Advisor of Life Sciences, added:
I am delighted to be joining at such an exciting time for ICG Life Sciences. The team boast an excellent track record both in regard to investing and developing market leading pharmaceuticals. I look forward to collaborating with the team to support the firm’s next phase of growth.
For further information please contact:
Clare Glynn
Head of Corporate Communications
T. +44 20 3545 1395
M. +44 7714 459 949
Email: [email protected]
About ICG
ICG provides flexible capital solutions to help companies develop and grow. We are a leading global alternative asset manager with over 30 years’ history, managing $82.1bn of assets and investing across the capital structure. We operate across four asset classes: Structured and Private Equity, Private Debt, Real Assets, and Credit.
We develop long-term relationships with our business partners to deliver value for shareholders, clients, and employees, and use our position of influence to benefit the environment and society. We are committed to being a net zero asset manager across our operations and relevant investments by 2040.
ICG is listed on the London Stock Exchange (ticker symbol: ICP). Further details are available at www.icgam.com. You can follow ICG on LinkedIn and X (Twitter).
Subscribe to our newsletters
Sign up for Regulatory News updates: click here
